Pipeline
← Отчётные звонки
01
02
03
04 05 06
Тон
A1 A2 A3
INCY
FY2026 Q1
Улучшается
Отчётный звонок Incyte Corporation
Вывод Buzzberg
Povacitinib Phase III trials met primary endpoint in vitiligo
Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M.
Вывод Buzzberg Povacitinib Phase III trials met primary endpoint in vitiligo Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M. Читать полный анализСвернуть анализ
Incyte delivers a strong Q1 2026 with 20% net sales growth, driven by the core business ex-Jakafi which grew 63%. Management emphasized multiple regulatory and clinical catalysts ahead, including a potential launch of Povorcitinib for HS, Monjuvi in 1L DLBCL, and the start of pivotal trials for 734 and 989. Q1 2026 total revenue was $1.27B (+21% YoY), with total net sales of $1.1B (+20%). Jakafi sales were $758M (+7%), while core ex-Jakafi grew 63% to $342M.
- NDA for Povorcitinib in HS accepted by FDA; positive Phase III results announced in vitiligo. Both support a major pipeline inflection point for the dermatology franchise.
- Ph3 trial for 989 in ET initiated with a flexible dose design; EHA update expected with ~100 ET patients and ~45+ MF patients.
- Ph3 trial for 734 (KRAS G12D inhibitor) in 1L pancreatic cancer has initiated.
Выручка$1.2727B-16% к/к
EPS$1.81+1% к/к
Операционная маржа25.47%Факт
Свободный денежный поток$0.3592B-31% к/к
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Regulatory
FDA accepted povacitinib NDA for hidradenitis suppurativa ahead of schedule
Guidance
Jackify XR expected to achieve 10-30% of Jackify business by 2029
Показать ещё 3 тезиса
Guidance
Core business ex-Jackify expected to approach $3-4 billion by 2030
Pipeline
KRAS G12D inhibitor 734 entering Phase III in first-line PDAC
Pipeline
989 ET Phase III trial on track for mid-year initiation
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $1.2727B | -16% к/к |
| EPS | $1.81 | +1% к/к |
| Операционная маржа | 25.47% | Факт |
| Свободный денежный поток | $0.3592B | -31% к/к |
| Капзатраты | $0.0102B | Факт |
| Чистая прибыль | $0.3033B | +1% к/к |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Выручка | FY2026 | $4.77B–$4.94B | $4.855B | Подтверждён |
| ВыручкаJAKAFI | FY2026 | $3.22B–$3.27B | $3.245B | Подтверждён |
| ВыручкаOPZELURA | FY2026 | $0.75B–$0.79B | $0.77B | Подтверждён |
| ВыручкаHEMONC | FY2026 | $0.8B–$0.88B | $0.84B | Подтверждён |
AI, капзатраты и спрос
Оценка менеджмента
Upbeat
Management highlighted strong sales growth, multiple regulatory milestones, and a confident outlook on pipeline catalysts, reflecting a positive and forward-looking tone.
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
Incyte believes that the approval of oral treatments for vitiligo will 'medicalize' the condition, expanding the overall market significantly. This is a key strategic bet that the category will grow beyond current treatment rates, driven by awareness and new oral options.
Доказательства
“these approvals will create awareness that vitiligo is a chronic inflammatory disorder. And I think that is important for everybody that's going to be in the vitiligo market. This is definitely about medicalizing the condition.”
The KRAS G12D inhibitor (734) combination with chemotherapy is being positioned as a potential standard-of-care shift in first-line pancreatic cancer. Incyte highlights the manageable tolerability without compromising chemo dose intensity as a key differentiator, with more data expected in H2 2026.
Доказательства
“Given how PDAC is treated in practice, especially in the first-line setting, that ability to combine effectively with both full-dose chemotherapy regimens is critical.”
The Phase 3 trial for 989 in ET includes a flexible dose escalation, starting at 750mg IV every two weeks with an option to increase to 2500mg based on early platelet response. This design is intended to address the heterogeneity in response and provides a template for upcoming MF trials.
Доказательства
“The trial will utilize a flexible dosing schedule, starting with 750 mg IV every two weeks, with a single dose escalation option built in... based on early platelet response.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 0. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.